Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099512 | 0.87 | IGF1R (0.75) | IGF1R | |
| SCHEMBL2932327 | 0.86 | IGF1R (0.72) | IGF1R | |
| SCHEMBL4029002 | 0.86 | IGF1R (0.74) | IGF1R | |
| SCHEMBL2941014 | 0.86 | IGF1R (0.82) | IGF1R | |
| SCHEMBL2999482 | 0.85 | IGF1R (0.73) | IGF1R | |
| SCHEMBL31572884 | 0.85 | IGF1R (0.82) | IGF1R | |
| SCHEMBL2938208 | 0.85 | IGF1R (0.80) | IGF1R | |
| SCHEMBL2940208 | 0.85 | IGF1R (0.74) | IGF1R | |
| SCHEMBL2939001 | 0.84 | IGF1R (1.00) | IGF1R | |
| SCHEMBL2937265 | 0.84 | IGF1R (0.84) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082329-A1 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | claimed |
| US-20090082329-A1 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| US-20090082329-A1 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| US-20090082329-A1 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-2035408-A1 | SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008000922-A1 | SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082329-A1 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | CHUK, BRAF, CNKSR1 | IGF1R 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.